Provided an effective anti-tumor drug to the children's department of the National Institute of Health

European company Recordati Rare Diseases set an ambitious goal back in the early 90s to provide effective treatment for people with rare diseases. This is its main principle:
"Every patient has the right to decent treatment."

Today, the company's arsenal includes dozens of state-of-the-art drugs, including "Cosmogen" (active ingredient - dactinomycin). It has no analogues in terms of effectiveness, and alternative treatment regimens are often more toxic and less effective.

50 vials to help children

Foundation "Zaporuka" purchased 50 bottles of Cosmegen and handed them over to the Children's Department of the National Cancer Institute (NCRI). Thanks to this, Ukrainian children will be able to pass Antitumor therapy according to international protocols right in Kyiv.

Quote from Hryhoriy Klymniuk, head of the NIR department:
"The availability of dactinomycin in Ukraine will allow us to provide highly effective therapy used by the world's leading cancer centers. Many thanks to the Foundation!"

Gratitude to international partners

Zaporuka Foundation expresses its gratitude to the company Recordati Rare Diseases Pros:

• covering all costs for the purchase and delivery of the drug to Ukraine;

• operational logistics;

• support for Ukrainian doctors in a difficult time.

Together to defeat the disease

We are proud to be able to contribute to the saving the lives of childrento help hospitals and families receive the best possible medical care.
 You can support the foundation's initiatives on its website:
https://zaporuka.org.ua
Our page in Facebook